Ross Givens
Chief Market Strategist
Ross Givens is a veteran trader with over 15 years of experience and a former VP at a major Wall Street investment bank. Specializing in small-cap stocks and momentum-driven plays, Ross identifies high-probability setups before they hit the mainstream. As Lead Strategist at Traders Agency, he has guided hundreds of successful trades and developed multiple flagship publications.
Bad News for the Market?
A Fed decision, weakening breadth and persistent bearish sentiment all point one way. But there’s a reason that setup may not play out the way most traders expect.
The AI Boom Is About to FLIP… Here’s What I’m Buying Instead
AI bubble stocks to buy are riskier than ever as costs hit zero. See why gold, oil, and copper beat the Mag 7 now.
Stocks at Insane Valuations?
The S&P 500 is still near record territory. But one measure of extreme valuation looks far less stretched than you’d expect – and the reason points to something happening underneath the surface.
The Big Economic Surprise
The headlines still sound gloomy. But one broad measure of economic activity just hit its strongest level in more than four years – and corporate forecasts are moving the same way.
Stocks Do THIS Right Before They EXPLODE Higher
Learn the breakout trading strategy that spots shallowing pullbacks before stocks explode higher, so you buy at the start, not after the move.
Is This Market Breaking Down?
Something underneath this market is deteriorating fast. But another signal is moving in the exact opposite direction.
History Says Stocks Are About to RUN… I Just Bought THIS One
Midterm elections 2026 history shows Q4 stocks rise 86% of the time. See the breakout stock I bought riding this bullish seasonal pattern.
Waiting for a Signal
September has a terrible historical reputation, but the market still hasn’t given traders the kind of volatility signal that has paid this year. Ross is watching something else instead.
The FDA Votes September 23rd... This Cancer Stock Could Go PARABOLIC
GRAIL Inc stock faces a binary FDA vote Sept 23rd on Galleri's cancer test. See what could send GRAL parabolic or crashing.
Will the Nasdaq Turn “Ugly” This Month?
A lot of traders are leaning the same way in Tech right now. If the market moves against them, the reaction could get much bigger than the initial move.
Wall Street Says Hair Loss Is the Next Ozempic... I Found the Stock to Watch
Veradermics stock (MANE) posted 4x placebo hair growth data. With 80M cash-paying patients, is this the next big pharma trade?
The Market is in for a Strange September
Some of the biggest forces in this market are pulling in different directions right now. Ross explains why that may create more opportunity beneath the surface than the indexes suggest.
Stop watching.
Start winning.
50,000+ traders get our daily brief before the market opens.
You're subscribed!
Check your inbox.
Free. No spam. Unsubscribe anytime.
